-
NEWS: Policy interventions could reduce chronic liver disease and liver cancer in Europe by up to 7% by 2030
Europe has the largest burden of diagnosed liver disease globally with almost 30 million people in the European Union alone estimated to be living with a chronic liver condition. Liver cirrhosis accounts for 1.8% of all deaths reported in Europe (170,000 deaths annually) with a 100% increase in cirrhosis deaths observed across the Eastern European […]
-
NEWS: Innovate UK-funded study reveals cost of air pollution related disease to local populations
Sandwell Metropolitan Borough Council has announced the successful completion of a groundbreaking pilot study on reducing poor air quality through community measures. The pilot study was launched in November 2022 by a consortium led by Enjoy the Air in partnership with Sandwell Metropolitan Borough Council to examine the link between air pollution, behaviour and the […]
-
Estimating the prevalence and future burden of rare genetic diseases: challenges and solutions
Genetic diseases are conditions caused by abnormalities in an individual’s DNA. They can be inherited from one or both parents, or can occur as a result of spontaneous genetic mutations. They may be caused by a mutation in a single gene (monogenic); by a chromosomal change where there are more or fewer copies than usual; […]
-
Early intervention for preventing NCDs: generating evidence for the health and economic impact, using microsimulation modelling
Non-communicable diseases (NCDs), including heart disease, stroke, cancer, diabetes and chronic lung disease, are the leading causes of death worldwide. A recent report by FP Analytics sets out the scale of the problem and the health and economic burden of NCDs. These conditions share a common set of risk factors of which the main ones […]
-
NEWS: HealthLumen to participate in air pollution project funded by UK Research and Innovation (UKRI)
HealthLumen is part of a consortium that has been a awarded a £50,000 Fast Start: Innovation grant to undertake a pilot project in Sandwell to reduce poor air quality through community measures. Air pollution is a major environmental cause of early death: it is also responsible for short- and long-term respiratory conditions such as asthma and lung […]
-
Impactability Modelling for Population Health Management
We’re looking forward to attending the NHS Population Health conference on 2nd November which will bring together NHS professionals to discuss PHM strategies aimed at addressing the many pressing issues facing the NHS. Our COO and co-founder Laura Webber, will be giving a talk on Population Health Management of non-communicable diseases: measuring the impact of […]
-
NEWS: Shift in England’s drinking during COVID-19 could lead to 150,000 more cases of disease by 2035
The Institute of Alcohol Studies has today released a report “Estimating the long-term health impacts of changes in alcohol consumption in England during the COVID-19 pandemic” which includes modelling undertaken by HealthLumen. The pandemic saw heavier drinkers consuming more alcohol and this trend is continuing. If consumption does not return to 2019 levels or lower, the modelling shows […]
-
NEWS: The Covid Hangover report launch
Our latest modelling project, undertaken for the Institute of Alcohol Studies, looks at how pandemic drinking patterns could impact alcohol-related disease and death.
-
Everything in moderation: the health and economic benefits of reducing salt consumption in the UK
We all know that too much salt is bad for our health! Consuming too much salt can lead to high blood pressure which can lead to a variety of different health conditions including stroke and coronary heart disease. These diseases combined, claim the lives of millions of people globally, and costs the NHS, as well […]
-
Reducing Failure Rates of Phase 3 Clinical Trials: how microsimulation modelling can assist
Of the three main phases of clinical trials, by far the most expensive part of the process is the Phase 3 trial, typically requiring from several hundred to several thousand participants and costing up to $20 million on average. Furthermore, the process is fraught with risks with up to 70% of Phase 2 trials and […]